The ToGA trial enabled the addition of trastuzumab to the first-line standard of care for patients with advanced HER2-positive GC and ushered in a new era of HER2-targeted therapy, while the benefits of trastuzumab as a neoadjuvant and adjuvant therapy have also been demonstrated. The gene discussed is ERBB2; the disease is gastric cancer.